Realization of a part of clinical trial called multicenter, randomized, double-blind, active-controlled study - Phase 3 monitoring of safety and efficacy of rolapitant in preventing chemotherapy-induced nausea and vomiting (CINV) in subjects receiving moderate emetogenic chemotherapy (MEC)